Boundless Bio Appoints Jennifer Lew to its Board of Directors

SAN DIEGO–()–Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that Jennifer Lew has been appointed to its Board of Directors and will serve as chairperson of the Audit Committee.

“I am pleased to welcome Jen to our Board of Directors,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “Jen is a senior biotech executive with a depth of expertise in financial operations and financing, investor relations, and strategic planning. Her demonstrated leadership in financial and strategic matters complements the notable skills and experience of our current directors and will be a valuable asset to our Board as Boundless Bio continues to grow and advance its pipeline.”

“I am delighted to join Boundless Bio and other members of the Board during this exciting time for the Company,” said Ms. Lew. “I look forward to supporting the executive team in the execution of its business plans and strategy to bring forward a pipeline of innovative therapies directed against ecDNA.”

Ms. Lew currently serves as Executive Vice President and Chief Financial Officer of Annexon Biosciences, where she led the company to completion of its successful initial public offering in 2020. Ms. Lew previously served as Chief Financial Officer for Aduro Biotech, Inc., where she played a key leadership role in financial and strategic matters, including Aduro’s initial public offering. Prior to Aduro, Ms. Lew held various roles of increasing responsibility at Dynavax Technologies Corporation and QRS Corporation. Ms. Lew began her career in the audit practice at Ernst & Young. She earned a BA in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive status).

About Boundless Bio

Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

For more information, visit

Follow us on LinkedIn and Twitter.


Recent Articles

Get a free copy of "Cracking the Generics Code"

Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.